BioNTech (NASDAQ:BNTX) Stock Rating Reaffirmed by HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $107.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 24.17% from the company’s current price.

BNTX has been the subject of several other reports. BMO Capital Markets decreased their price objective on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a report on Thursday, March 21st. JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. UBS Group reduced their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. Finally, Oppenheimer assumed coverage on shares of BioNTech in a report on Friday, January 5th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech presently has an average rating of “Hold” and a consensus target price of $120.40.

BioNTech Stock Down 0.3 %

BNTX opened at $86.17 on Wednesday. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $91.33 and a 200-day moving average price of $97.49. BioNTech has a twelve month low of $85.21 and a twelve month high of $125.83. The stock has a market capitalization of $20.49 billion, a price-to-earnings ratio of 20.92 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Equities research analysts forecast that BioNTech will post -1.67 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. CWM LLC raised its stake in BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares in the last quarter. State of Wyoming purchased a new stake in shares of BioNTech in the second quarter valued at $26,000. Frazier Financial Advisors LLC purchased a new stake in shares of BioNTech in the fourth quarter valued at $30,000. Finally, Covestor Ltd purchased a new stake in shares of BioNTech in the third quarter valued at $32,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.